The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)Enterprise IT Expenditure Survey: Google Cloud is expected to be the first choice for 50% of the respondents. Tae Kim, a science and technology columnist, wrote that according to a recent survey, Google Cloud has risen rapidly in the enterprise AI expenditure competition and may become the winner. According to the 2025 CIO survey released by Piper Sandler, 81 CIOs were asked about their budget priorities in different suppliers and technical fields. According to the survey, 87% of CIOs surveyed expect to increase the IT budget in 2025, which is the highest proportion of the survey since 2020. In this survey, the status of Google Cloud has risen significantly, surpassing Microsoft and OpenAI to become the "most strategic" AI supplier, with a support rate of 27%, a significant increase from 15% six months ago. Relatively speaking, Microsoft's support rate dropped from 33% to 24%. When asked which cloud company they plan to use to test or implement AI projects next year, 50% of the respondents chose Google Cloud, making it the top AI infrastructure provider. In addition, Harsh Kumar, a Piper semiconductor analyst, pointed out that these results are also beneficial to Invista, because all cloud companies are the main buyers of AI chips in NVIDIA. Kumar estimates that the entire AI chip market will have more than $500 billion in business opportunities by 2028.Huadong Pharmaceutical has established a new company in Jiaxing with a registered capital of 60 million yuan. According to Tianyancha App, Huadong Pharmaceutical (Jiaxing) Co., Ltd. was recently established with Zhu Li as its legal representative and a registered capital of 60 million yuan. Its business scope includes drug wholesale, drug retail, decoction service for Chinese herbal pieces, third-class medical device operation, drug Internet information service, drug import and export, third-class medical device rental and medical device Internet information service. According to shareholder information, the company is wholly owned by Huadong Pharmaceutical (000963).
Domestic futures opened mixed at night, with Shanghai copper down 0.56%, Shanghai zinc down 0.39%, Shanghai nickel up 1.75%, iron ore up 0.06%, coking coal up 0.42% and crude oil up 1.15%.Deutsche Bank appointed MARCUS CHROMIK as the new CRO.ByteDance and Peking University set up the Joint Lab of Bean Bag Large Model System Software. On the evening of December 12th, the signing ceremony of Peking University-ByteDance Joint Lab of Bean Bag Large Model System Software and the academic seminar of "Intelligent Software Technology and Ecology for Large Model" were held in Yingjie Exchange Center, Peking University. Experts attending the meeting agreed that it is of great significance to promote the deep integration of Industry-University-Research to promote the breakthrough of core technologies of artificial intelligence. The establishment of this joint laboratory is an important milestone in collaborative innovation between schools and enterprises, and will jointly promote the technological innovation and application development of large-scale model system software based on the advantages of both parties. (Sina Technology)
The survey shows that the European Central Bank is expected to cut interest rates for the fourth time this year to provide support for the economy, and the European Central Bank is bound to cut interest rates for the fourth time this year, loosening the troubled euro zone economy with the inflation rate approaching 2%. According to the survey, all the respondents except one analyst predicted that the European Central Bank would cut the deposit interest rate by 25 basis points to 3% again on Thursday. Only JPMorgan Chase is expected to cut interest rates by more than 50 basis points, believing that the recent data show that economic growth and inflation are weakening.Guoxuan Hi-Tech: It plans to invest a total of 2.514 billion euros to build new energy battery production bases in Slovakia and Morocco. Guoxuan Hi-Tech announced that the company plans to invest in Slovakia with its own and self-raised funds to build high-performance lithium batteries and supporting projects with an annual output of 20GWh, with a total investment of no more than 1.234 billion euros. On the same day, it was announced that the company plans to invest in Morocco with its own and self-raised funds to build a high-performance lithium battery and supporting projects with an annual output of 20GWh, with a total investment of no more than 1.28 billion euros.The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)
Strategy guide 12-14
Strategy guide 12-14
Strategy guide 12-14